Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Biovac has secured a $108.3 million financing package that will allow the South African pharma company to build the continent ...

Genentech has launched the “Life Doesn’t Wait” campaign to mark World Hemophilia Day, dialing up its focus on patient stories ...

Neurogene is looking to make the leap from a clinical biotech to a commercial biopharma with its lead gene therapy and has ...

Biogen and Minor League Baseball’s Durham Bulls are joining forces to celebrate “America 250” in the Triangle Community.  | ...